This site uses some unobtrusive cookies to store information on your computer. These cookies are essential, as the site won't work as expected without them. These cookies are set when you submit a form, login or interact with the site by doing something that goes beyond clicking on simple links. 

We also use some non-essential cookies to anonymously track visitors or enhance your experience of the site. If you're not happy with this, we can disable these these cookies but some features of the site may not work. By using our site you accept the terms of our Privacy Policy.

Close

Trojan Ethical Income Fund

The investment objective of Trojan Ethical Income Fund is to seek to provide income with the potential for capital growth in the medium term. Its investment policy is to invest substantially in UK and overseas equities. Trojan Ethical Income Fund may also invest in fixed interest securities, indices, deposits, collective investment schemes and money market instruments.

The fund will invest in accordance with the parameters of its ethical investment criteria, which consider ethical issues in relation to: fossil fuels, pornography, tobacco and certain types of armaments. A document setting out the fund’s ethical investment criteria is available here.

In addition to the O share class referred to on this page, I & S Classes are also available. Please contact us for more information.

Derivatives may be employed for the purposes of efficient portfolio management.

Investment Performance will not be shown until one calendar year after the fund's launch due to regulatory requirements. Similarly, no information relating to Trojan Ethical Income Fund is included in either the Interim Report or Annual Report.

'O' Share Class Price 17/08/2017
116.22p
Accumulation Shares
Income Shares
111.01p
Fund Size
£61M

July 2017

The Fund produced a return of -0.3% in June compared to +1.2% for the FTSE All-Share Index (TR).

Although many of the Fund’s investments performed well, the absolute return generated during the month was limited by weak performance from the Fund’s UK pharmaceutical holdings.

The announcement of a failed lung cancer drug trial caused AstraZeneca to fall by more than 15%, effectively reversing the gains of the year to date and returning the share price to its January lows. This was a blow to Astra’s important immuno-oncology franchise. The share price adjustment has reflected the future loss of revenue and we believe the valuation is now reasonable.

GlaxoSmithKline’s quarterly report was received only slightly more positively.  The strategy laid out by Emma Walmsley, the new CEO, was greeted with scepticism by a market weary of new initiatives to enhance R&D productivity. This combined badly with a modest downgrade to earnings guidance to precipitate a -4.1% intraday fall. We continue to hold both stocks on attractive yields, in excess of 4.8% and 5.2% respectively.

On a more positive note the Fund’s ethical investment criteria mean that the portfolio is not exposed to the tobacco sector which, following the US regulator’s announced intention to place further restrictions on the industry, was the largest detractor from the FTSE All Share Index’s return.  We rarely speak about what we do not own but it is important to highlight how the ethical criteria have the potential to enhance returns by excluding sectors where the activities of an industry expose it to higher regulatory or legislative scrutiny.

At the end of the period the Fund declared a provisional interim dividend of 1.735p which equates to a 1.6% yield on the ex-dividend share price. The relatively modest 2% uplift is a reflection of a desire to rebalance the total annual distribution in favour of the final dividend.  The income account remains robust and the prospects for the full year are encouraging.

 

 

 

Top 10 HoldingsFund (%)
Unilever 4.5
GlaxoSmithKline 3.3
Lloyds 3.3
Novartis 3.0
Royal Mail 2.9
National Grid 2.7
Nestlé 2.7
Compass Group 2.6
AstraZeneca 2.6
American Express 2.5
Total Top 10 30.1
36 other holdings 59.8
Cash & equivalent 10.1
Total 100.0

 

Past performance is not necessarily a guide to future performance. The value of a fund and any income from it may go down as well as up and investors may get back less than they invested. Changes in rates of exchange may cause the value of investments to go up or down. Any data is provided for information only and should not be reproduced, published or disseminated in any manner. Although Troy considers data to be reliable, no warranty is given as to its accuracy or completeness. Any comparisons against indices are for illustrative purposes only.

How to Invest

You may invest directly, via a broker or adviser, or through a number of online fund platforms.

Find Out More

  • Fund Manager
    Hugo Ure
  • Inception Date
    06/01/2016
  • Currency
    £ Sterling
  • Available Share Class
    O, I, S
  • ISIN (O Class)
    GB00BYMLFK38 (Acc)
    GB00BYMLFL45 (Inc)
  • Bloomberg (O Class)
    TEIFOAC_LN (Acc)
    TEIFOIN_LN (Inc)
  • Sedol (O Class)
    BYMLFK3 (Acc)
    BYMLFL4 (Inc)

Related Literature